Home| Netegrity (acquired by IBM) |
$2.18 to $73.20 | 3487% |
| Inhibitex (acquired by |
$2.35 to $24.08 | 925% |
| Cellstar | $1.44 to $13.50 | 837% |
| Iomega | $3.25 to $13.90 | 328% |
| Nanophase | $3.75 to $16.75 | 347% |
| Immunomedics | $1.44 to $29.12 | 1922% |
| Total Renal Care | $3.12 to $26.95 | 741% |
| Voxware | $ .90 to $10.31 | 1046% |
| Corvas | $3.00 to $23.25 | 675% |
| Cytogen | $2.12 to $17.50 | 725% |
| Verilink | $3.00 to $14.62 | 387% |
| GeneLabs | $2.31 to $10.72 | 364% |
WE CLOSED ADMA BIOLOGICS AT $6.10 FOR A 85% GAIN!
WE CLOSED CURIS, INC. AT $2.62 FOR A 80% GAIN!
WE CLOSED ANAVEX LIFE SCIENCES AT $3.95 FOR A 56% GAIN!
ALSO, WE CLOSED CATALYST PHARMACEUTICALS AT $5.24 FOR A 54% GAIN!
AND, WE CLOSED NEOS THERAPEUTICS AT $3.60 FOR A 71% GAIN!
The mid to late April Newsletter is now live and featured are EVEN TWO MORE BIOTECH picks, both trading at around $2.75. One specializes in gene therapies and has collaborations with around half dozen institutions, including MIT; while the other, a CHANNELED STOCK PICK, that worked wonders for us before, develops products to improve biodefenses.
The early to mid-May Newsletter will feature a maker of anti-infective agents that has recently had two NDAs granted by the FDA, trading at around $2.75; while the other pick develops therapies for GI diseases and is a BUY of SEVEN ANALYSTS and trades at about $3.55.